Extracellular vesicles isolation–Developing new devices
One of the main technical challenges to studying EVs is to isolate them without interfering with their structure, in order to be able to reveal their functions and to use them as biomarkers. Moreover, the new area of therapeutically using EVs needs clinical grade methods of isolation.
Although ultracentrifugation is commonly used for isolation of EVs, it is highly time-consuming, requires an ultracentrifuge and results in relatively low recovery of EVs, and it causes non-vesicular macromolecule contamination and aggregation of EVs that can lead to masking of surface antigens.
Nanovex is always developing new EV-related products for research support.
Among the new EV-related products, the team is has developed an isolation column to use instead of the latest ultracentrifugation steps.Nanovex Eviso-Columns, allows to skip the ultracentrifugation step in is typical differential centrifugation method for EVs isolation, and obtain purified exosomes in PBS in a short time. Under ideal conditions, SEC purification of exosomes is able to remove >99% of contaminating free proteins.
To concern a direct isolation of exosomes from cell culture medium without any pre-enrichment steps, Nanovex proposesthe Exo-beads for immunoisolation and immunofluorescent isolation strategiesto detectTSG101 protein involved in MVB biogenesis of exosomes.
Opportunity in EU projects
Nanovex team is interested in collaborating in EU projects to develop a diagnostic device for rapid detection of EVs from blood-specific pathology. We are looking for research centers/SME specialized in (i)the development of new biomarkers, (ii)microfluidic devices, (iii)clinical test, for a joint development.